O-RAN-ALLIANCE
25.2.2020 10:02:10 CET | Business Wire | Press release
The O-RAN Alliance (O-RAN) and the Telecom Infra Project (TIP) have announced today a liaison agreement that ensures alignment in the shared focus area of developing interoperable open Radio Access Network (RAN) solutions.
The O-RAN Alliance is focused on the development of open, intelligent, virtualized and interoperable RAN specifications. The Alliance has already created 31 specifications, with 37 demonstrations of the technology at past MWC events, global plugfests, and more than 1 000 000 lines of code released in partnership with the Linux Foundation. Operators have begun to announce network implementations.
O-RAN Alliance’s mission and focus complements TIP’s mission of deploying end-to-end disaggregated telecom infrastructure in varying environments. With the liaison agreement O-RAN and TIP are now reaching a new level of collaboration for open RAN. The liaison allows for sharing information, referencing specifications and conducting joint testing and integration efforts.
“This new collaboration framework between O-RAN and TIP, two major initiatives in the area of open networking, will support our mission to re-shape the RAN industry towards open and intelligent mobile network infrastructure,” said Alex Jinsung Choi, COO of the O-RAN Alliance and SVP Strategy & Technology Innovation, Deutsche Telekom. “Alignment on O-RAN interoperability efforts will help the industry to speed up the delivery of commercial open RAN solutions. The establishment of the first joint O-RAN Open Test and Integration Center (OTIC) with the TIP Community Lab in Berlin is a concrete step to facilitate this multi-community approach.”
“TIP’s OpenRAN solutions are an important element of our work to accelerate innovation across all elements of the network including Access, Transport, Core & Services. Across the TIP community, we are seeing increasing demand and have achieved meaningful progress with OpenRAN deployments around the world,” said Attilio Zani, Executive Director, Telecom Infra Project. “With this collaboration framework in place, TIP and O-RAN will work together to develop interoperable 5G RAN solutions. One of our first outputs will be the release of the OpenRAN 5GNR NR Base Station Platform requirements document with normative references to the O-RAN specifications.”
About O-RAN Alliance
O-RAN Alliance is a world-wide community of more than 160 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, O-RAN Alliance’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN-compliant mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, O-RAN Alliance publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For a short video describing O-RAN’s progress, see www.o-ran.org/videos
For more information please visit www.o-ran.org
About Telecom Infra Project
TIP is a collaborative telecom community that is evolving the infrastructure that underpins global connectivity. TIP’s mission is to accelerate the pace of innovation in next generation telecom networks, through the design, build, test and deployment of standards-based, open and disaggregated end-to-end solutions. Over the past four years, TIP has driven substantial innovation across all elements of the network including Access, Transport, Core & Services, while spanning urban through to rural market use cases. To date, it has 13 Community Labs which test, validate and integrate solutions, embarked on field trials in Africa, Latin America, Middle East and Europe. The recently launched TIP Exchange hosts 45 products from 28 member companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
